Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-11-07
2010-10-26
Nickol, Gary B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S135100, C424S141100, C424S142100, C514S04400A, C536S023100
Reexamination Certificate
active
07820160
ABSTRACT:
The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
REFERENCES:
patent: 5521004 (1996-05-01), Reiners et al.
patent: 5629284 (1997-05-01), Unoki et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5733871 (1998-03-01), Alps et al.
patent: 5994524 (1999-11-01), Matsushima et al.
patent: 6024956 (2000-02-01), Matsushima et al.
patent: 6048972 (2000-04-01), Matsushima et al.
patent: 6068840 (2000-05-01), Matsushima et al.
patent: 6083907 (2000-07-01), Uchida et al.
patent: 2003/0072739 (2003-04-01), Takada et al.
patent: 2004/0219129 (2004-11-01), Yoshida et al.
patent: 07-009641 (1994-04-01), None
patent: 8-27021 (1996-01-01), None
patent: 8-73498 (1996-03-01), None
patent: PCT/US95/08781 (1996-02-01), None
patent: WO 99/34493 (1998-07-01), None
patent: WO 99/16463 (1999-04-01), None
patent: WO 99/38971 (1999-08-01), None
Shoyab et al., Ampriregulin-associated protein: complete amion acid sequence of a protein produced by the 12-0-tetradecanoylphorbol-13-acetate-treated human breast adenocarcinoma cell line MCF-7, Biochem. Biophys. Res. Comm. 179(1):571, 1991 (abstract only).
Agrawal, S. (1996)Trends Biotechnol. vol. 14, No. 10, pp. 376-387.
Berk, Bradford C. et al. (May 1991) “Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty”J. Am. Coll Cardiol. 17(6 Suppl B):111B-117B.
Braasch, D.A. (2002)Biochemistry. vol. 41, No. 14, pp. 4503-4510.
Branch, A.D. (1998)Trends Biochem. Sci. vol. 23, No. 2, pp. 45-50.
Griffith, M. (1997) “Midkine and Secondary Neurulation”Teratology. vol. 55, pp. 213-223.
Kojima et al. (Mar. 1996) “Human Ryudocan from Endothelim-like Cells Binds Basic Fibroblast Growth Factor, Midkine, and Tissue Factor Pathway Inhibitor.”The Journal of Biological Chemistry. vol. 271, No. 10, pp. 5914-5920.
McCune, et al. Sep. 2001, J. Am. Med. Assoc. vol. 286, No. 10, pp. 1149-1152.
Muramatsu, H. et al. (1996) “Enzyme-Linked Immunoassay for Midkine, and Its Application to Evaluation of Midkine Levels in Developing Mouse Brain and Sera from Patients with Hepatocellular Carcinomas”J. Biochem. vol. 119, pp. 1171-1175.
Muramatsu, H. et al. (1993)Developmental Biology. vol. 159, pp. 392-402.
Ohyama, Y. et al. (1994) “Isolation and identification of midkine and pleiotrophin in bovine follicular fluid”Mol. Cell Biol. vol. 105, pp. 203-208.
Ratovitski et al. (1993) “Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases”The Journal of Biological Chemistry. vol. 273, No. 6, pp. 3654-3660.
Sun, Xue-Zhi et al. (Dec. 1997) “An Immunohistochemical Study of Radial Glial Cells in the Mouse Brain Prenatally Exposed to γ-irradiation”Journal of Neuropathology and Experimental Neurology. vol. 56, No. 12, pp. 1339-1348.
Tamm, I. et al. (2001)The Lancet. vol. 358, pp. 489-497.
Wang, Sha-Yan et al. (1998) “Midkine exists in astrocytes in the early stage of cerebral infarction”Developmental Brain Researchvol. 106, pp. 205-209.
Rha, S.Y. et al. “Comparison of Biological Phenotypes According to Midkine Expression in Gastric Cancer Cells and Their Autocrine Activities Could be Modulated by Pentosan Polysulfate”Cancer Letters, 1997, pp. 37-46, vol. 118.
Yoshida, Y. et: al. “Midkine is present in the early stage of cerebral infarct”,Dev. Brain Res., 1995, 85:25-30.
Gewirtz, A.M. et al. “Facilitating oligonucleotide delivery: helping antisense deliver on its promise”Proc. Natl. Acad. Sci. 1996, vol. 93, pp. 3161-3163.
Green et al. “Antisense oligonucleotides: An evolving technology for the modulation of gene expression in human disease”Antisense Therapy in Human Disease, 2000, 191:93-105.
Jen et al. “Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies”Stem Cells, 2000, 18:307-319.
Carmeliet et al. “Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostatis”Cardio. Res., 1998, 39:8-33.
Hayashi et al. “Antisense oligoribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury”Am. J. Physiol. Heart Circ. Physiol., 2005, 288:H2203-H2209.
Bennet et al. “Antisense therapy for angioplasty restenosis”Circulation, 1995, 92:1981-1993.
Garas et al. “Overview of therapies for prevention of restenosis after coronary interventions”Pharma.&Therap., 2001, 92:165-178.
Morishita et al. “Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides”J. Clin. Invest., 1994, 93:1458-1464.
Horiba et al. “Midkine (MK) plays a crucial role in neointimal formation”J. Amer. College Cardio., 1991, 33(2, Supp A):229A-230A.
Fazekas et al., Journal of Immunological Methods (1980) 35:1-21.
Galfre et al., Nature (1979) 277:131-133.
Galfre et al., Methods in Enzymology (1981) 73:3-46.
Giovannangeli et al., PNAS USA (1993) 90:10013-10017.
Haeuptle et al., Nucleic Acids Research (1986) 14(3):1427-1448.
Kadomatsu et al., Biochemical and Biophysical Research Communications (1988) 151(3):1312-1318.
Kaneda et al., J. Biochem. (1996) 119:1150-1156.
Kearney et al., J. Immunology (1979) 123(4):1548-1550.
Kohler and Milstein, Eur. J. Immunol. (1976) 6:511-519.
Kohler and Milstein, Nature (1975) 256:495-497.
Kojima et al., JBC (1996) 271(10):5914-5920.
Kumar et al., Arteriosclerosis, Thrombosis, and Vascular Biology (1997) 17:2238-2244.
Kumar et al., Circulation (1997) 96:4333-4342.
Kuo et al., JBC (1990) 265(31):18749-18752.
Li et al., Science (1990) 250(4988):1690-1694.
Maeda et al., JBC (1996) 271(35):21446-21452.
Margulies et al., Cell (1976) 8:405-415.
Mercator Study Group, Circulation (1992) 86:100-110.
Muramatsu, Develop. Growth & Differ. (1994) 36:1-8.
Nakamura et al., Genes to Cells (1988) 3:811-822.
Nobuyoshi et al., JACC (1991) 17(2):433-439.
Parker, Experimental Atherosclerosis (1960) 36:19-53.
Rauvala, The EMBO Journal (1989) 8(10):2933-2941.
Ross, New England Journal of Medicine (1986) 314(8):488-500.
Ross, Nature (1993) 362:800-809.
Schwartz et al., Circulation Research (1995) 77:445-465.
Shulman et al., Nature (1978) 276:269-270.
Stein et al., Cancer Research (1988) 48:2659-2668.
Stein et al., Science (1993) 261:1004-1012.
Tomomura et al., JBC (1990) 265(18):10765-10770.
Trowbridge, J. Exp. Med. (1978) Jul. 1:313-323.
Tsutsui et al., Biochemical and Biophysical Research Communications (1991) 176(2):792-797.
Walder et al., PNAS USA (1988) 85:5011-5015.
Webster et al., American Journal of Pathology (1974) 76(2):245-264.
Weintraub et al., New England Journal of Medicine (1994) 331:1331-1337.
Wellstein et al., JBC (1992) 267(4):2582-2587.
Yelton et al., Curr. Top. Microbiol. Immunol. (1978) 81:1-7.
Horiba Mitsuru
Ikematsu Shinya
Kadomatsu Kenji
Muramatsu Takashi
Sakuma Sadatoshi
Kaufman Claire
Medical Therapies Limited
Morrison & Foerster / LLP
Nickol Gary B.
LandOfFree
Midkine inhibitory compositions for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Midkine inhibitory compositions for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Midkine inhibitory compositions for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4210323